Cell-bound complement activation products

Exagen Announces Acceptance of Multiple Abstracts at ACR 2022 Annual Meeting

Retrieved on: 
Tuesday, September 20, 2022
ACR, Adoption, Therapy, Precision medicine, Laboratory, MAP, Movement, COVID-19, American College, Medicare, Twitter, Machine learning, SARS-COV-2, Fibromyalgia, Private Securities Litigation Reform Act, Smallpox Vaccination Campaign of 2003, Pennsylvania Convention Center, Patient, XGN, Physician, 2021 Essex County Council election, Vaccination, Use, Solution, Annual report, Rheumatology, CA, Science, Rheumatoid arthritis, Vista, SAN, Research, Conference, GLOBE, SLE, RNA-Seq, SEC, Cell-bound complement activation products, Synovial membrane, Algorithm, Artificial intelligence, Medical imaging, Pharmaceutical industry, Vaccine

SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American College of Rheumatologys (ACR) annual meeting, ACR Convergence 2022, being held November 10-14, 2022, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.

Key Points: 
  • SAN DIEGO, Sept. 20, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, announced today the acceptance of nine abstracts at the 2022 American College of Rheumatologys (ACR) annual meeting, ACR Convergence 2022, being held November 10-14, 2022, at the Pennsylvania Convention Center in Philadelphia, Pennsylvania.
  • In addition, data from Exagens research on machine learning in patients with fibromyalgia has been accepted for an oral presentation.
  • Exagens President and Chief Executive Officer, Ron Rocca, shared, Exagen is honored to have nine scientific abstracts accepted for ACRs 2022 annual conference, with a featured poster focusing on AVISE RADR and a podium presentation.
  • Such forward-looking statements include, but are not limited to, statements regarding our clinical research and development teams scientific abstracts for presentation at ACR Annual Conference and the potential to lead to increased adoption of any AVISE test.

Exagen Inc. Collaboration Leads to Characterization of Broad Autoreactivity in Severe COVID-19 Patients

Retrieved on: 
Thursday, September 1, 2022
CA, COVID-19, CEO, Technology, Division, Research, SAN, Emory University, Doctor of Philosophy, Solution, Precision medicine, PACS, Physician, Area studies, SEC, Laboratory, XGN, Vista, Severe acute respiratory syndrome coronavirus 2, GLOBE, Medicare, Movement, Therapy, Twitter, Cell-bound complement activation products, Annual report, Private Securities Litigation Reform Act, COVID, Trial of the century, Patient, Emory School, Pharmaceutical industry, Nature, Lipotriches exagens, Rheumatology

Exagens clinical test offerings, run on samples from severe COVID-19 patients, helped researchers from Emory characterize the autoimmune profiles induced by SARS-CoV-2 infection.

Key Points: 
  • Exagens clinical test offerings, run on samples from severe COVID-19 patients, helped researchers from Emory characterize the autoimmune profiles induced by SARS-CoV-2 infection.
  • These efforts will assess the importance of long-term autoimmune monitoring in those patients experiencing lasting symptoms following acute pulmonary infection, including those caused by SARS-CoV-2.
  • Mathew Woodruff, PhD is a researcher at the Lowance Center for Human Immunology and the Division of Rheumatology at Emory School of Medicine.
  • We are excited to have partnered with Exagen on this important work investigating the origins of emerging self-targeted antibody responses in severe COVID-19.

Exagen Inc. Expands Coverage with Alivio Health, Partnering to Provide More Accurate Diagnostic Testing with AVISE® CTD and AVISE® Lupus

Retrieved on: 
Monday, May 16, 2022
Physician, Disease, Private Securities Litigation Reform Act, U.S. Securities and Exchange Commission, Lipotriches exagens, Lupus, Cell-bound complement activation products, Degenerative disease, Health, Patient, SLE, End organ damage, COVID-19, CTD, Medicare, SAN, Partnership, Technology, Prognosis, Rheumatoid arthritis, Therapy, Movement, Twitter, SEC, GLOBE, Security (finance), CEO, Annual report, Rheumatology, Health insurance, Medical imaging, Pharmaceutical industry

The agreement also makes AVISE diagnostic testing available as an in-network benefit.

Key Points: 
  • The agreement also makes AVISE diagnostic testing available as an in-network benefit.
  • Lupus is tricky to diagnose, and it currently takes an average of six years before being confirmed with the disease.
  • Providing greater access to accurate testing means a better chance of catching lupus early.
  • Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.

Exagen Inc. Announces New PLA Code and Medicare Pricing for Proprietary AVISE® Lupus Test

Retrieved on: 
Wednesday, May 11, 2022
MAC, Private Securities Litigation Reform Act, Securities and Exchange Commission (Philippines), Lipotriches exagens, PLA, Lupus, Cell-bound complement activation products, Patient, SLE, AMA, COVID-19, CTD, Medicare, SAN, Indian Medical Association, Technology, Prognosis, Rheumatoid arthritis, American Medical Association, Therapy, Movement, Twitter, SEC, GLOBE, Security (finance), CEO, Annual report, Rheumatology, Pharmaceutical industry, Noridian Mutual Insurance Company

Noridians decision to price AVISE Lupus follows the approval by the American Medical Association (AMA) CPT Editorial Panel of Proprietary Laboratory Code (PLA) code 0312U for AVISE Lupus.

Key Points: 
  • Noridians decision to price AVISE Lupus follows the approval by the American Medical Association (AMA) CPT Editorial Panel of Proprietary Laboratory Code (PLA) code 0312U for AVISE Lupus.
  • Noridians pricing of AVISE Lupus along with AMA CPTs issuance of PLA Code 0312U both reflect the proprietary and novel aspects of AVISE Lupus which combine Cell-Bound Complement Activation Products (CB-CAPs) along with an algorithmic SLE-likelihood assessment to aid providers in the evaluation of suspected SLE patients.
  • Ron Rocca, President and CEO of Exagen Inc. shared, being the recipient of this dedicated PLA code marks an important milestone for Exagen.
  • Furthermore, commercial payors are under no obligation to recognize a PLA code or to reimburse at the Medicare rate.

Exagen Inc. Reports First Quarter 2022 Results

Retrieved on: 
Wednesday, May 11, 2022
Janssen, Private Securities Litigation Reform Act, WellCare, U.S. Securities and Exchange Commission, Lupus, Cell-bound complement activation products, Webcast, Patient, Goal, Investment, Solution, Review, American Medical Association, Centene Corporation, Investor relations, COVID-19, CTD, Research, Medicare, SAN, Omicron, Interest, Technology, Prognosis, Rheumatoid arthritis, Therapy, Movement, Twitter, SEC, Growth, GLOBE, Record, Security (finance), Annual report, Rheumatology, Video game, Pharmaceutical industry, Lipotriches exagens

SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March31, 2022.

Key Points: 
  • SAN DIEGO, May 11, 2022 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN),a leading provider of autoimmune testing solutions, today reported financial results for the quarter ended March31, 2022.
  • Delivered 30,903 AVISE CTD tests, including AVISE Lupus, in the first quarter of 2022, a 6.5% increase over the first quarter of 2021.
  • Since the launch of AVISE CTD in 2012 through the first quarter of 2022, we have delivered over 646,000 of these tests.
  • Testing gross margin was 44.0% in the first quarter of 2022, compared to 54.2% in the first quarter of 2021.

Exagen Announces Five-Week Campaign for Lupus Awareness Month

Retrieved on: 
Sunday, May 1, 2022
Awareness, CEO, LinkedIn, SLE, Cell-bound complement activation products, Patient, Twitter, GLOBE, Research, Learning, Prognosis, Interest, Lupus Foundation of America, Technology, SAN, Diagnosis, Facebook, Rheumatoid arthritis, Lupus, Motivation, Instagram, Public relations, Medical imaging, Medical device, Lipotriches exagens

SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-week awareness campaign to highlight important and impactful work being done to help those suffering from Systemic Lupus Erythematosus (SLE).

Key Points: 
  • SAN DIEGO, May 01, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced, in recognition of Lupus Awareness Month, the launch of a five-week awareness campaign to highlight important and impactful work being done to help those suffering from Systemic Lupus Erythematosus (SLE).
  • For each of the five weeks in the month of May, Exagen will focus on a different theme that, when combined, provides a holistic view of the work being done within the lupus community.
  • To better deliver on these initiatives, and to properly shed light on the challenges those with lupus face, Exagen is partnering with the Lupus Foundation of America, Lupus LA, and patient advocates throughout the month.
  • Ron Rocca, President and CEO of Exagen, shared, The landscape of lupus therapies and testing has changed over the past few years.

Exagen to Announce First Quarter 2022 Financial Results on May 11, 2022

Retrieved on: 
Monday, April 25, 2022
Prognosis, Twitter, Lupus, Interest, GLOBE, Patient, SAN, Review, Technology, Rheumatoid arthritis, Cell-bound complement activation products, Webcast, Lipotriches exagens, Video game

SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after the market close on Wednesday, May 11, 2022.

Key Points: 
  • SAN DIEGO, April 25, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, will release financial results for the quarter ended March 31, 2022, after the market close on Wednesday, May 11, 2022.
  • Ron Rocca, Exagens President and Chief Executive Officer, Kamal Adawi, Chief Financial Officer, and Mark Hazeltine, Chief Operating Officer, will host a conference call to review the Companys results at 4:30 PM ET (1:30 PM PT).
  • A replay of the conference call will be available until Wednesday, May 18, 2022, at 11:59 PM ET (8:59 PM PT).
  • Additionally, a recording of the webcast will be available using the link on the Exagen investor relations website approximately 30 minutes after the call concludes.

Exagen Inc. to Participate in Investor Summit Group’s Q2 Conference

Retrieved on: 
Wednesday, April 20, 2022
Prognosis, U.S. Securities and Exchange Commission, The Westin New York Grand Central Hotel, COVID-19, Security (finance), Annual report, Lupus, Interest, Private Securities Litigation Reform Act, Patient, Conference, Technology, Rheumatoid arthritis, Movement, Cell-bound complement activation products, SEC, Rheumatology, Lipotriches exagens, Therapy, Medicare, Pharmaceutical industry

Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Groups Q2 Conference, which takes place May 3rd - 4th, 2022, in New York City at the Westin New York Grand Central Hotel.

Key Points: 
  • Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, today announced its participation in Investor Summit Groups Q2 Conference, which takes place May 3rd - 4th, 2022, in New York City at the Westin New York Grand Central Hotel.
  • Interested parties may access the webcast of the presentation using a link on Exagens website at https://investors.exagen.com/events .
  • Exagen cautions you that statements contained in this press release regarding matters that are not historical facts are forward-looking statements.
  • The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved.

Exagen Inc. Expands In-Network Access with Evolutions Healthcare Systems

Retrieved on: 
Wednesday, March 30, 2022
Private Securities Litigation Reform Act, SLE, Cell-bound complement activation products, Financial compensation, Therapy, Degenerative disease, Partnership, Streamlining Claims Processing for Federal Contractor Employees Act, Health care, SEC, CEO, U.S. Securities and Exchange Commission, Independent Healthcare Providers Network, Security (finance), Political lists, Technology, Rheumatoid arthritis, Lupus, Review, International, Lipotriches exagens, COVID-19, GLOBE, Rheumatology, Movement, CTD, SAN, Health, Patient, Prognosis, Pharmaceutical industry, Health insurance, Physician, Hospital

SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, announced today that AVISE tests have entered into an in-network agreement with Evolutions Healthcare Systems offering access to enhanced care to participating members.

Key Points: 
  • SAN DIEGO, March 30, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, announced today that AVISE tests have entered into an in-network agreement with Evolutions Healthcare Systems offering access to enhanced care to participating members.
  • Exagen is dedicated to transforming the care continuum for patients suffering from debilitating and chronic autoimmune diseases by enabling timely differential diagnosis and optimizing therapeutic intervention.
  • In addition to our network of healthcare professionals, Evolutions provides a comprehensive suite of Healthcare Management solutions and Claims Processing services.
  • Exagen cautions you that statements in this press release regarding matters that are not historical facts are forward-looking statements.

Exagen Inc. Expands In-Network Benefit with Additional 22.7 Million Lives

Retrieved on: 
Tuesday, March 22, 2022
Private Securities Litigation Reform Act, SLE, Cell-bound complement activation products, Therapy, Degenerative disease, Partnership, SEC, CEO, WellCare, U.S. Securities and Exchange Commission, Security (finance), Technology, Rheumatoid arthritis, Lupus, Lipotriches exagens, COVID-19, Centene Corporation, GLOBE, Rheumatology, Movement, CTD, SAN, Patient, Prognosis, Medical imaging

SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, announced today that AVISE tests will soon surpass 90 million lives as an in-network benefit for patients.

Key Points: 
  • SAN DIEGO, March 22, 2022 (GLOBE NEWSWIRE) -- Exagen Inc.(Nasdaq: XGN),a leading provider of autoimmune testing solutions, announced today that AVISE tests will soon surpass 90 million lives as an in-network benefit for patients.
  • Effective June 1, 2022, AVISE test offerings become an in-network, covered benefit with Centene Corporation, including its subsidiary WellCare Health Plans, providing enhanced care to over 22.7 million members.
  • Exagen cautions you that statements in this press release regarding matters that are not historical facts are forward-looking statements.
  • The inclusion of forward-looking statements should not be regarded as a representation by Exagen that any of its plans will be achieved.